PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer

Bairavi Shankar¹, Jarushka Naidoo^{1

2}

Affiliations

¹ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
² Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA.

Editorial

Bairavi Shankar et al. J Thorac Dis. 2018 Nov.

. 2018 Nov;10(Suppl 33):S4034-S4037.

doi: 10.21037/jtd.2018.09.46.

Bairavi Shankar¹, Jarushka Naidoo^{1

2}

¹ Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
² Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS. Pillai RN, et al. Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28. Cancer. 2018. PMID: 28960263 Free PMC article.

1. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26:2375-91. - PMC - PubMed
1. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015;33:1430-7. 10.1200/JCO.2014.59.0703 - DOI - PMC - PubMed
1. Robert C, Schachter J, Long G, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015;372:2521-32. 10.1056/NEJMoa1503093 - DOI - PubMed
1. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med 2018;378:2093-104. 10.1056/NEJMoa1801946 - DOI - PMC - PubMed
1. Reck M, Rodríguez-Abreu D, Robinson A, et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed